What is Semaglutide?

Semaglutide is a modified GLP-1 receptor agonist designed to last far longer than native GLP-1. The molecule activates the GLP-1 receptor, slows gastric emptying early in treatment, increases glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, and reduces appetite through central satiety pathways. [1][2]

For chronic weight management, the strongest evidence comes from large STEP trials of once-weekly subcutaneous semaglutide 2.4 mg, including weight-loss, maintenance, and two-year follow-up data. [6][8][9]

Semaglutide also has large outcome trials in type 2 diabetes, cardiovascular-risk reduction, chronic kidney disease, and oral semaglutide cardiovascular outcomes. Those results make it very different from research-market peptides with only mechanism or animal data. [11][10][12][13]

What Semaglutide is investigated for

Semaglutide evidence is grouped by practical use case and injectable and oral route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Body-weight reduction and maintenance

Injectable, Oral

95% Strong

Semaglutide is strongly supported for weight management when used as the labeled drug product in the right population and clinical setting. [1][6]

Human evidence

STEP trials show large and sustained weight reductions with subcutaneous semaglutide 2.4 mg, including maintenance data and two-year follow-up. [6][8][9]

Animal / mechanistic evidence

Mechanistic support comes from GLP-1 receptor effects on appetite, satiety, gastric emptying, and energy intake, but the human trial evidence is the main reason confidence is high. [1]

Type 2 diabetes glycemic control

Injectable, Oral

92% Strong

The diabetes use case is strong, but dose, route, and concomitant glucose-lowering therapy matter for hypoglycemia and tolerability. [2][3]

Human evidence

Semaglutide injection and tablets have labeled diabetes indications, and STEP 2 shows weight and glycemic data in adults with type 2 diabetes and overweight or obesity. [2][3][7]

Animal / mechanistic evidence

The incretin mechanism is glucose-dependent, increasing insulin and reducing glucagon when glucose is elevated. [2]

Cardiovascular-risk reduction in selected populations

Injectable, Oral

88% Strong

Cardiovascular benefit should be interpreted by trial population and label, not as a blanket claim for every semaglutide user. [10][13]

Human evidence

SELECT, SUSTAIN-6, and SOUL support cardiovascular benefit in defined high-risk populations and product contexts. [10][11][13]

Animal / mechanistic evidence

Mechanistic explanations likely include weight, glycemic, blood-pressure, lipid, inflammatory, and direct tissue effects, but human trials carry the claim. [10]

Kidney protection in type 2 diabetes with CKD

Injectable

82% Strong

Confidence is high for the studied population, but it should not be generalized to kidney wellness claims outside that population. [12]

Human evidence

FLOW reported kidney benefit in patients with type 2 diabetes and chronic kidney disease. [12]

Animal / mechanistic evidence

The route-relevant mechanism is likely tied to metabolic, hemodynamic, and cardiometabolic effects rather than direct kidney-targeted peptide replacement. [12]

Neurodegenerative disease

Oral

45% Preliminary

Large Alzheimer's trials did not confirm clinical benefit, so semaglutide remains an investigated GLP-1 therapy rather than an established neurodegenerative-disease treatment. [44][43]

Human evidence

The EVOKE and EVOKE+ phase 3 trials tested oral semaglutide in early symptomatic Alzheimer's disease, but sponsor topline results reported no statistically significant reduction in disease progression versus placebo. [43][44]

Animal / mechanistic evidence

GLP-1 receptor biology remains under study in neurodegenerative disease, including Parkinson's disease, but this does not establish semaglutide as a neuroprotective treatment. [45]

Evidence snapshot

Overall confidence

Strong

92%

Semaglutide has one of the strongest human evidence profiles in this catalog: large randomized obesity trials, diabetes trials, FDA labeling, and hard-outcome studies all support specific clinical use cases. [6][7][10][12]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

95%

Human evidence

Strong

Large STEP, SUSTAIN, SELECT, FLOW, and SOUL datasets support weight, glycemic, cardiovascular, kidney, and oral semaglutide outcomes in the populations studied. [6][11][10][12][13]

82%

Animal / preclinical

Strong

Nonclinical and pharmacology support explains GLP-1 receptor activity, but human trials and approved labeling are the main reason confidence is high. [1][2]

90%

Mechanism support

Strong

GLP-1 receptor activation links the observed outcomes to appetite regulation, gastric-emptying effects during initiation, glucose-dependent insulin secretion, and glucagon suppression when glucose is elevated. [1][2][3]

Forms & administration

Semaglutide administration is product-specific. Injection pens, oral tablets, weight-management labels, cardiovascular-risk labels, MASH labeling, and type 2 diabetes labels should not be collapsed into one generic peptide protocol. [1][2][3]

InjectableOral

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Wegovy injection starts at 0.25 mg once weekly and escalates through 0.5 mg, 1 mg, and 1.7 mg before a usual maintenance range of 1.7-2.4 mg once weekly. Ozempic injection uses a separate type 2 diabetes label with 0.25 mg initiation and 0.5-2 mg once-weekly dosing after escalation. Wegovy tablets start at 1.5 mg once daily and titrate to 25 mg once daily; semaglutide diabetes tablet labels use their own daily tablet strengths. [1][2][3]

Frequency

Injectable semaglutide products are dosed once weekly. Oral semaglutide tablets are dosed once daily. Weekly injection schedules should stay weekly, and daily tablet schedules should stay daily. [1][2][3]

Timing Considerations

Weekly injections can be scheduled on the same day each week at any time of day, with or without meals. Tablets are a morning empty-stomach routine: take with plain water only, use a small water amount, swallow whole, and wait at least 30 minutes before food, drink, or other oral medicines. [1][3]

Cycle Length

Semaglutide is managed as ongoing treatment, not a short peptide cycle. Injection titration commonly takes about 4 months to reach maintenance, while Wegovy tablet titration takes about 3 months. Weight-management trials followed people for about 1-2 years, and maintenance depended on continuing therapy. [1][8][9]

Protocol Notes

Do not convert between injection and tablet doses by matching milligrams. Route, absorption, device, product strength, and indication all change the schedule. Unapproved or compounded semaglutide claims should be kept separate from FDA-approved pen and tablet labels. [1][3][4]

What to expect

First weeks

Appetite is usually the first change people notice: smaller portions feel more manageable and fullness can arrive sooner. [1][6]

3-6 months

Scale and waist changes usually become more visible, and appetite control can feel steadier as the routine settles. [6][8]

1 year and beyond

Many responders maintain a lower weight with continued treatment, and cardiometabolic markers may remain improved while the medication effect is present. [8][9][10]

After stopping

Appetite can return toward baseline and weight regain is common after semaglutide is stopped; blood pressure, glucose, and lipid improvements may also soften. [8][9][22]

Safety profile

Semaglutide has a well-characterized prescription-drug safety profile. The main practical issues are GI intolerance, dehydration risk, gallbladder and pancreatitis warnings, diabetes-medication interactions, retinopathy caution in diabetes, pregnancy planning, and the boxed thyroid C-cell tumor warning. [1][2][3]

Common side effects

Nausea [1]
Vomiting [1]
Diarrhea [1]
Constipation [1]

Cautions

Thyroid C-cell tumor warning [1]
Pancreatitis and gallbladder disease [1]
Insulin or sulfonylureas [2][3]
Pregnancy planning [2]
Compounded or unapproved GLP-1 products [4]

Who Semaglutide is not for

Route-specific avoid and medical-review notes:

MTC or MEN2 history
Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2. [1][2]
Pregnancy planning
Labels instruct discontinuation before planned pregnancy because of semaglutide exposure and long washout considerations. [2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Documented interactions

Insulin or sulfonylureas
Hypoglycemia risk can increase when semaglutide is combined with insulin secretagogues or insulin, so glucose-lowering therapy may need adjustment. [2][3]
Levothyroxine or monitored oral drugs
Oral semaglutide delays gastric emptying and can change oral-drug exposure; the label specifically reports higher levothyroxine exposure and calls for closer monitoring of narrow-therapeutic-index or clinically monitored oral medicines. [3]

Pairing notes

Works well with

Nutrition and activity intervention Injectable, Oral

Nutrition and activity give semaglutide's appetite and weight-maintenance effects a structure to work inside: calorie targets, movement, and adherence routines support the medication effect rather than replacing it. [1][6]

Not recommended with

Other GLP-1 or incretin agonists without clinician direction Injectable, Oral

Semaglutide already delivers GLP-1 appetite, gastric-emptying, and glucose effects; adding another GLP-1 or incretin drug can duplicate nausea, vomiting, dehydration, and glucose-management risks, so it belongs in prescriber-managed medication therapy. [1][2]

Regulatory status

United States

United States: FDA-approved semaglutide drug products exist for specific indications and routes. Unapproved or compounded GLP-1 products are a separate regulatory and safety issue. [1][2][4]

Route	FDA drug approval	503A compounding
Injectable	Approved Semaglutide injection appears in FDA-approved drug labeling for products such as Wegovy and Ozempic; indications and dosing depend on the specific product. [1][2]	Not Listed FDA warns that unapproved GLP-1 products used for weight loss can create dosing, ingredient, quality, and adverse-event risks. This is separate from FDA-approved semaglutide products. [4]
Oral	Approved Semaglutide tablets appear in FDA-approved labeling for oral products; tablet indications and administration requirements are not interchangeable with injectable products. [1][3]	Not Listed FDA-approved tablets have specific formulation and administration requirements; compounded or research-market oral products should not be treated as interchangeable with labeled tablets. [3][4]

Injectable

FDA drug approval

Approved

Semaglutide injection appears in FDA-approved drug labeling for products such as Wegovy and Ozempic; indications and dosing depend on the specific product. [1][2]

503A compounding

Not Listed

FDA warns that unapproved GLP-1 products used for weight loss can create dosing, ingredient, quality, and adverse-event risks. This is separate from FDA-approved semaglutide products. [4]

Oral

FDA drug approval

Approved

Semaglutide tablets appear in FDA-approved labeling for oral products; tablet indications and administration requirements are not interchangeable with injectable products. [1][3]

503A compounding

Not Listed

FDA-approved tablets have specific formulation and administration requirements; compounded or research-market oral products should not be treated as interchangeable with labeled tablets. [3][4]

International

International status depends on country, product name, indication, route, and local prescribing rules.

Sports & competition

Semaglutide is not named as a prohibited substance in the reviewed 2026 WADA list, but athletes still need to follow medication, prescription, and event-specific rules. [15]

How it works

Semaglutide is a long-acting GLP-1 receptor agonist. The practical effect is appetite and calorie-intake reduction, plus glucose-dependent insulin release and lower glucagon when glucose is elevated, without making hypoglycemia irrelevant when insulin or sulfonylureas are used. [1][2][6]

It also delays gastric emptying, which supports fullness but helps explain nausea, reflux-type symptoms, dehydration risk after vomiting or diarrhea, and oral-medicine timing concerns. [1][2][3]

Route and formulation matter: injectable and oral semaglutide have different exposure rules, and approved-product evidence does not make compounded, salt-form, or research-market products equivalent. Product and route drive the evidence. [1][3][4]

Research gaps & open questions

What the current literature has not yet settled about Semaglutide:

Route-to-route substitution remains a practical risk. More direct comparisons between approved tablet and injection products would help readers understand what is formulation-specific rather than molecule-wide. [1][3]

Long-term maintenance, discontinuation strategy, lean-mass preservation, nutrition quality, and access remain important questions even with strong efficacy evidence. [8][9]

Common questions

Is semaglutide a peptide?

Yes. It is a modified GLP-1 peptide analog, but it should be treated as a prescription drug product rather than a generic research peptide. [1]

Are oral and injectable semaglutide interchangeable?

No. They are different product routes with different dose forms and administration rules, even though the active ingredient is semaglutide. [1][3]

Does weight loss stay after stopping?

STEP 4 and related follow-up data show that continued treatment supports maintenance better than withdrawal; stopping can be followed by weight regain. [8][9]

Myths & misconceptions

Myth

Any semaglutide product is basically the same as Wegovy or Ozempic.

Reality

FDA-approved products have reviewed formulation, labeling, dose delivery, and quality controls. FDA has separately warned about unapproved GLP-1 products used for weight loss. [4][1]

Myth

Semaglutide is only a weight-loss drug.

Reality

Weight management is a major use case, but semaglutide also has diabetes, cardiovascular, oral-formulation, and kidney-outcome evidence in defined populations. [2][10][12]

History & discovery

Semaglutide moved GLP-1 therapy from diabetes glucose control into obesity and broader cardiometabolic outcomes. Its history matters because the same incretin biology supported injectable, oral, and obesity-dose programs rather than one narrow obesity discovery. [2][3][6][11]

SUSTAIN-6 established cardiovascular-outcome context in type 2 diabetes, and STEP 1 made once-weekly semaglutide 2.4 mg a modern obesity-drug reference point. [11][6]

SELECT, FLOW, SOUL, MASH research, and FDA GLP-1 safety materials widened the evidence story while keeping approved formulations separate from unapproved GLP-1 products and later liver-disease questions. [10][12][13][21][4]

Published research 42 studies

[1]

WEGOVY (semaglutide) injection and tablets prescribing information

U.S. Food and Drug Administration, 2026. regulatory.

[2]

OZEMPIC (semaglutide) injection prescribing information

U.S. Food and Drug Administration, 2025. regulatory.

[3]

RYBELSUS and OZEMPIC tablets prescribing information

U.S. Food and Drug Administration, 2026. regulatory.

[4]

FDA's concerns with unapproved GLP-1 drugs used for weight loss

U.S. Food and Drug Administration. official guidance.

[5]

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list

U.S. Food and Drug Administration. regulatory.

[6]

Once-Weekly Semaglutide in Adults with Overweight or Obesity

New England Journal of Medicine. human clinical.

[7]

Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes

The Lancet. human clinical.

[8]

Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance

JAMA. human clinical.

[9]

Two-year effects of semaglutide in adults with overweight or obesity

Nature Medicine. human clinical.

[10]

Semaglutide and cardiovascular outcomes in obesity without diabetes

New England Journal of Medicine. human clinical.

[11]

Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

New England Journal of Medicine. human clinical.

[12]

Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes

New England Journal of Medicine. human clinical.

[13]

Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes

New England Journal of Medicine. human clinical.

[14]

STEP 1: semaglutide 2.4 mg weight-management trial registry record

ClinicalTrials.gov. clinical trial registry.

[15]

The 2026 Prohibited List

World Anti-Doping Agency, 2025. regulatory.

[16]

Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology

Ophthalmology, 2026. review.

[17]

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

JAMA cardiology, 2026. human clinical.

[18]

Ocular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations

Journal of the Chinese Medical Association : JCMA, 2026. review.

[19]

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

JAMA internal medicine, 2026. human clinical.

[20]

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

The New England journal of medicine, 2025. human clinical.

[21]

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

The New England journal of medicine, 2025. human clinical.

[22]

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis

Obesity reviews : an official journal of the International Association for the Study of Obesity, 2025. review.

[23]

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Lancet (London, England), 2025. human clinical.

[24]

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

The New England journal of medicine, 2025. human clinical.

[25]

Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials

Diabetes care, 2025. review.

[26]

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

Metabolism: clinical and experimental, 2025. review.

[27]

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis

The New England journal of medicine, 2024. human clinical.

[28]

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

Nature medicine, 2025. human clinical.

[29]

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials

Metabolism: clinical and experimental, 2024. review.

[30]

Evaluating the safety profile of semaglutide: an updated meta-analysis

Current medical research and opinion, 2024. review.

[31]

Clinical Pharmacokinetics of Semaglutide: A Systematic Review

Drug design, development and therapy, 2024. review.

[32]

Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

The American journal of cardiology, 2024. review.

[33]

Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review

International journal of molecular sciences, 2024. review.

[34]

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials

Lancet (London, England), 2024. review.

[35]

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

BMJ (Clinical research ed.), 2024. review.

[36]

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2024. review.

[37]

Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial

Diabetes, obesity & metabolism, 2024. review.

[38]

The Weight-loss Effect of GLP-1RAs Glucagon-Like Peptide-1 Receptor Agonists in Non-diabetic Individuals with Overweight or Obesity: A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials

The American journal of clinical nutrition, 2023. review.

[39]

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis

Journal of the ASEAN Federation of Endocrine Societies, 2022. review.

[40]

Semaglutide for the treatment of overweight and obesity: A review

Diabetes, obesity & metabolism, 2023. review.

[41]

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis

Annals of internal medicine, 2020. review.

[42]

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

The lancet. Diabetes & endocrinology, 2019. review.